NCT03606694 is a Phase 2 clinical trial of Dihydromyricetin in Type 2 Diabetes Mellitus, sponsored by University of Guadalajara.

Who is sponsoring NCT03606694?

NCT03606694 is sponsored by University of Guadalajara.

What drugs are being tested in NCT03606694?

Interventions in NCT03606694: Dihydromyricetin, Metformin.

What condition does NCT03606694 study?

NCT03606694 studies Type 2 Diabetes Mellitus.

Is NCT03606694 still recruiting?

NCT03606694 is currently status unknown. Last updated 23 May 2023.

Last reviewed 2023-05-23 · How we verify

NCT03606694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus

Status unknown Phase 2 Last updated 23 May 2023

What this trial tests

Phase 2 trial testing Dihydromyricetin in Type 2 Diabetes Mellitus in 24 participants. Status unknown.

Timeline

30 October 2019

Primary endpoint
28 December 2022

30 December 2023

Quick facts

Lead sponsor	University of Guadalajara
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	30 October 2019
Primary completion	28 December 2022
Estimated completion	30 December 2023
Sites	1 location across Mexico

Drugs / interventions tested

Dihydromyricetin — full drug profile →
Metformin (metformin) — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

University of Guadalajara

Who can join

Adults 30 to 60, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity and insulin secretion, that above mentioned findings show that dihydromyricetin has an excellent potential effect in the treatment of type 2 diabetes mellitus patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Dihydromyricetin inhibits African swine fever virus replication by downregulating toll-like receptor 4-dependent pyroptosis in vitro.
Chen Y, Song Z, Chang H, Guo Y, et al · · 2023 · cited 25× · PMID 37438783 · DOI 10.1186/s13567-023-01184-8
Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2.
Prabhu D, Rajamanikandan S, Sureshan M, Jeyakanthan J, et al · · 2021 · cited 9× · PMID 33933885 · DOI 10.1016/j.jmgm.2021.107920

Verify or expand the search:

Other trials of Dihydromyricetin

Trials testing the same drug.

NCT05623501 — Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease · Phase 1 · not yet recruiting

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other University of Guadalajara trials

Trials by the same sponsor.

NCT06915701 — "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" · Phase 2, PHASE3 · recruiting
NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chron · NA · recruiting
NCT07056712 — Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion · NA · not yet recruiting
NCT07408947 — Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an · completed
NCT06829186 — The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03606694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Guadalajara
Last refreshed: 23 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03606694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing